The prolonged usage of antiepileptic drugs has necessitated the need to study their toxicological profiles using in experimental animals. The toxicological effects of carbamazepine (CBZ) and levetiracetam (LEV) on some biochemical and haematological parameters were evaluated in rats. Haematological parameters evaluated include packed cell volume (PCV), Haemoglobin (Hb) and white blood cell (WBC), while some biochemical parameters studied were liver enzyme tests such as alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipid profiles tests such as total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL). In addition, the body weight and morphological assessment of the vital body organs were determined. Results showed that CBZ and LEV did not significantly affect the haematological parameters. Animals treated with CBZ showed a significant increase in TC and HDL levels at 400 and 1000 mg/kg doses. There was no significant increase in the TC, HDL, LDL and TG in rats treated with LEV. CBZ and LEV treated animals at the doses of 400 and 1000 mg/kg showed a significant increase in body weights from the 6 th day after commencement of treatment. There was also a significant increase in the weights of the liver, kidney and heart of the animals treated with CBZ and LEV. The colour and texture of the organs did not change. However, no appreciable weight increase was observed with the lung.
. It was therefore, important to study and ascertain the toxicological effects of carbamazepine (CBZ) and levetiracetam (LEV) on some biochemical and haematological parameters using rats.
Materials and Methods

Experimental animals
Twenty four adult albino rats of both sexes weighing between 100 -200 g were obtained from the animal house of the
Department of Pharmacology and Toxicology, Madonna
University Elele. The animals were housed in cages and were allowed to acclimatize for a period of one week before commencement of experiment.
Collection of drug
Carbamazepam (NOVARTIS, Switzerland) and Levetiracetam (UCB Inc. USA) were sourced in a local Nigerian Pharmacy.
Experimental procedure
The animals were grouped into seven (A-G) groups of six animals each. The animals in groups A, B and C received 100, 400 and 1000 mg/kg of CBZ, respectively while those in groups D, E and F received 100, 400 and 1000 mg/kg of LEV, respectively, lastly group G received 2.5 ml/kg of the vehicle and was used as the untreated control. All treatments were administered orally daily for a period of three weeks. At the end of the 21 days, the animals were anaesthetized with chloroform first and then cardiac puncture technique was used to collect blood samples from the rats. The blood from rat was put in two different bottles -a plain bottle and an anticoagulant (EDTA)
bottle. The rat was later sacrificed and the organs harvested, cleaned and weighed. The blood samples were transferred in plain tubes without any additives and were allowed to coagulate. The coagulated blood was centrifuged and the serum separated from the cells with a micropipette. The serum was stored in a freezer at 20 ˚C and the EDTA blood was stored in a fridge at 4 ˚C before they were subjected to haematological and biochemical analysis.
Liver function analysis
Alkaline phosphatase
Two test tubes were labelled sample and standard and 1. 
Alanine aminotransferase (ALT)
Method: same as AST It was then calculated using this formula:
Packed cell volume (PCV)
Microhaematocrit method as described by (Chessbrough 2004) 6 A plain capillary tube was three quarter filled with well mixed anti coagulated blood and one end was sealed with plastacine.
It was then spun using a microhaematocrit centrifuge at 1200 RPM for 5 minutes, immediately after centrifuging, the PCV was read with a hand held microhaematocrit reader, the base of the red cell column was aligned (above the sealant) on the zero mark and the top of the plasma column on the 100 mark, the PCV was read off from the scale, the reading point is the top of the cell column, just below the buffy coat layer (consisting of white blood cells and platelets)
Total white blood cell count (WBC)
Manual method as described by (Chessbrough 2004) 6 was used.
A 0.3ml of diluting fluid (Turk's solution) was dispensed into a tube then 0.02ml of thoroughly mixed anti-coagulated blood was added. The counting chamber was charged; this was done by sliding a cover slip into position over the grid areas of the counting chamber and pressing down on each edge until rainbow color (Newton rings) was seen. The diluted blood sample was mixed using a pipette held at an angle of about 45 degree, one of the grids of the chamber was filled with the sample.
The chamber was left undisturbed for two minutes to allow the cells settle. The chamber was placed on a microscope stage.
Using 10 X objective iris sufficiently closed to give a good contrast, the ruling of the chamber and the white cells was focused, and the cells in the four large corners square of the chambers were counted.
The number of white cells per litre of blood counted was reported using the following simple calculation:
 The total number of cells counted was divided by two  The figure obtained was divided by ten.
Lipid Profile
Estimation of total serum cholesterol
Oxidation method was used. The serum was diluted with distilled water in the ratio of 1:20; the cholesterol standard was diluted with glacial acetic acid in the ratio of 1:20. The test tube rack was swirled for 10 seconds to mix the contents of each test tube; the test tubes were immediately placed in boiling water for exactly 90 seconds. The test tubes were cooled in running tap water for 5 minutes; the absorbance was read at 560nm against the blank, using dry cuvette. The colour was stable for 15 minutes.
Triglyceride
Two test tubes were labelled standard and test, 0.1 ml of triglyceride reagent was added and 2µl of standard solution and sample were also added into the appropriate tubes, it was mixed and incubated at 37°C for 5 minutes and read in a spectrophotometer at 547nm against water and blank
Conc. of test =
High density lipoprotein
A 200 µl of sample/standard was added into a test tube followed by 500 µl of HDL dilute participant. The solution was mixed and allowed to stand for 10 minutes at room temperature and centrifuged at 400 RPM for 10 minutes. The clear supernatant was separated and the HDL cholesterol was determined using the total; cholesterol enzymatic end point method.
Low density lipoprotein
The formula below was used to determine the LDL-cholesterol
Statistical analysis
The results were expressed as mean ± standard error of mean (SEM). Statistical analysis was performed by one-way ANOVA with LSD as multiple comparison to evaluate differences between the control and test groups. Values at p < 0.05 were considered significant. Table 1 shows the effects of carbamazepine and levetiracetam on the PCV, Hb and WBC at different concentrations of 100, 400 and 1000 mg/ml. Table 2 shows the effects of carbamazepine and levetiracetam on the lipid profile at different concentrations of 100, 400 and 1000 mg/ml. the lipid profile include TC, TAG, HDL and LDL Table 3 shows the effects of carbamazepine and levetiracetam on the liver enzymes at different concentrations of 100, 400 and 1000 mg/ml. The liver enzymes include ALP, ALT and AST. Table 4 shows the effects of carbamazepine and levetiracetam on the body weight of the rats at different concentrations of 100, recorded at 3 days intervals until the 21st day
Results
Effects of Carbamazepine and Levetiracetam on PCV, Hb and WBC
Effects of Carbamazepine and Levetiracetam on lipid profile
Effects of Carbamazepine and Levetiracetam on Liver Enzymes
Effects of Carbamazepine on Body Weight
Effects of Carbamazepine and Levetiracetam on Organ
Weight Table 5 shows the effects of carbamazepine and levetiracetam on the weight of the organs at different concentrations of 100, 400 and 1000 mg/ml. The organs evaluated include the liver, kidney, lung and heart. Table 6 shows the effects of carbamazepine and levetiracetam on the colour and texture of the vital organs at different concentrations of 100, 400 and 1000 mg/ml. The vital organs include the liver, kidney, heart and lung. Values are in mean±SD, n = 6, Values are in mean±SD, n = 6, * significantly different at (p<0.05) from the control. TC = Total Cholesterol, TAG = triglyceride, HDL = High density lipoprotein, LDL= Low density lipoprotein
Effects of Carbamazepine and Levetiracetam on the Colour and Texture of Vital Organs
Discussions
There was no significant difference in the PCV of groups treated with 100 and 1000 mg/kg of CBZ, but there was a significant increase in PCV (p=0,05) for those that received the 400 mg/kg dose when compared with the control ( there was no statistically significant increase in the TC, HDL-C, LDL-C and TG in patients treated with LEV for more than six months. There was no significant change in the LDL and TG levels for treated animals when compared with the control. From our findings, it appears that the newer AEDs like levetiracetam is preferred, especially for patients who are predisposed to cardiovascular problems than the first line AEDs -CBZ because of non elevation of serum cholesterol. Groups treated with 400 and 1000 mg/kg of CBZ showed significant increase in ALT (p=0.05), AST (p=0.05), and ALP (p=0.05), but there was no significant change in the level of these enzymes for those treated with 100 mg/kg of CBZ (Table   3) (Table 4 ). There has been a report on clinically significant weight gain with several AEDs, both the first-line and second-line generations. CBZ is associated with weight gain 18 . This is of clinical importance in various ways.
When there are changes in weight, there are usually associated health hazards, body image and self-esteem are impaired, and this can lead to noncompliance with therapy 19 . It can also lead to obesity, another serious risk factor for cardiovascular diseases and type 2 diabetes.
The liver weight for CBZ treated animals showed a significant increase at 1000 mg/kg dose (p=0.05) ( Table 5 ). This study also implies that increase in liver weight for CBZ treated animals is dose related as there was no significant change for those treated with 100 and 400 mg/kg when compared with the control.
There was also a significant increase in the weights of kidney (p=0.05) and heart (p=0.05) for groups treated with 1000 mg/kg dose of CBZ, while those treated with 100 and 400 mg/kg doses showed no significant change indicating that effect of CBZ on heart and kidney weights is also dose-dependent. On the contrary, the lungs of treated animals (with CBZ and LEV)
showed no significant change in weight when compared with the control. The group treated with LEV showed a significant increase in the liver weight (p=0.05) at all the concentrations used. There was also a significant increase in the weights of kidney (p=0.05) and heart (p=0.05) for groups treated with 1000 mg/kg dose of LEV.
CBZ showed no effect on colour of organs of treated animals (table 6) 
Conclusion
The findings exhibited that administration of carbamazepine and levetiracetam in rats over a long period of time has marked effects on some haematological and biochemical parameters.
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